tiprankstipranks
Trending News
More News >
Nuwellis (NUWE)
NASDAQ:NUWE
Advertisement

Nuwellis (NUWE) AI Stock Analysis

Compare
712 Followers

Top Page

NUWE

Nuwellis

(NASDAQ:NUWE)

Rating:45Neutral
Price Target:
$5.50
▲(5.36% Upside)
Nuwellis's overall stock score is primarily impacted by its financial struggles, including consistent losses and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to negative earnings. While the earnings call and corporate events show some positive strategic initiatives, they are overshadowed by the immediate financial challenges.
Positive Factors
Pediatric Revenue
Strong growth in Pediatric revenue, up 28% year-over-year, following the addition of three new accounts during the quarter.
Reimbursement
The CMS will reassign the Aquadex ultrafiltration code to increase reimbursement rates, which should provide a profitable reimbursement pathway and expand the number of patients who can receive the therapy.
Revenue Growth
The slight revenue beat in 2Q24 is a positive sign that the company is expanding its presence within the medical system and driving increased utilization of consumables.
Negative Factors
Cash Flow
Even with the higher reimbursement rates, the company is not expected to operate on a positive cash flow basis through at least 2026.
Pediatric Utilization
The y/y decline in the quarter in pediatric utilization gives some concern.
Profitability
The timeline towards profitability remains unclear, likely requiring additional dilutive capital raises, which dampens the investment outlook.

Nuwellis (NUWE) vs. SPDR S&P 500 ETF (SPY)

Nuwellis Business Overview & Revenue Model

Company DescriptionNuwellis (NUWE) is a medical technology company specializing in innovative solutions for fluid management and treatment of patients with chronic conditions. The company operates primarily in the healthcare sector, focusing on developing advanced medical devices and therapies aimed at improving patient outcomes in conditions related to fluid overload, such as heart failure and kidney disease. Nuwellis's core products include its proprietary devices designed to assist in the safe and effective removal of excess fluid from patients, thereby enhancing their quality of life and reducing hospital readmissions.
How the Company Makes MoneyNuwellis generates revenue through the sale of its medical devices and related products, which are sold to hospitals, healthcare providers, and clinics. The company's revenue model is primarily based on direct sales of its proprietary fluid management devices, as well as recurring revenue from consumables and accessories that accompany these devices. Key revenue streams include product sales, service contracts, and potential licensing agreements. Additionally, Nuwellis may benefit from partnerships with healthcare institutions and collaborations with other medical technology companies, which can enhance market reach and provide access to new customer segments.

Nuwellis Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: -5.09%|
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Negative
The earnings call highlights several strategic initiatives and resolutions, such as pediatric revenue growth and successful transition plans, which are promising for future growth. However, the current financial performance is challenged by a significant revenue decline, reduced gross margins, and increased operating losses. While there are positive steps being taken, the immediate financial indicators present a negative outlook.
Q2-2025 Updates
Positive Updates
Pediatric Revenue Growth
Pediatric revenues increased by 23% compared to the second quarter of 2024, reflecting strong demand from established hospital customers and new centers.
Resolution of Sterilization Vendor Issue
The temporary back order issue due to a sterilization vendor was resolved in the first week of July, allowing the company to build inventory and support future sales.
Transition to KDI Precision Manufacturing
Transition to KDI Precision Manufacturing is expected to result in operational efficiencies and cost savings over the next 12 months.
Increased Reimbursement for Heart Failure
Reimbursement increased from $413 to $1,639 per day for outpatient clinics, which is expected to drive growth in the heart failure segment.
Successful Capital Raise
The company completed a $5 million gross capital raise, bolstering its financial position and supporting core growth initiatives.
Negative Updates
Overall Revenue Decline
Total revenue for the second quarter was $1.7 million, down 21% year-over-year from $2.2 million.
Gross Margin Decrease
Gross margin decreased to 55.5% from 67.2% in Q2 2024, largely due to under-absorption of fixed overhead because of lower production volumes.
Increased Operating Loss
Operating loss for Q2 was $2.9 million, compared to $2.3 million in Q2 2024.
Net Loss Attributable to Common Shareholders
Net loss attributable to common shareholders was $12.6 million, or a loss of $60.99 per share, compared to $7.7 million or a loss of $791.82 per share in 2024.
Termination of REVERSE-HF Clinical Trial
The REVERSE-HF clinical trial was terminated to reallocate approximately $4 million to higher impact growth areas.
Company Guidance
During the Nuwellis Second Quarter 2025 Earnings Conference Call, management provided key guidance and insights into their strategic focus and financial performance. The company reported a revenue of $1.7 million for the second quarter, representing a 21% year-over-year decline, primarily due to a temporary back order issue with a sterilization vendor affecting approximately $400,000 in revenue. Despite this, pediatric revenues grew by 23%, while heart failure and critical care revenues saw declines of 53% and 35%, respectively. The gross margin dropped to 55.5% from 67.2% the previous year, attributed to lower production volumes. Operating expenses increased slightly by 2% to $3.9 million, resulting in an operating loss of $2.9 million. The company ended the quarter with $4.5 million in cash and remains debt-free, supported by a recent $5 million capital raise. Going forward, Nuwellis plans to focus on key growth areas in cardiac surgery, pediatrics, and outpatient heart failure, with expectations of operational efficiencies and cost savings from transitioning manufacturing to KDI Precision Manufacturing.

Nuwellis Financial Statement Overview

Summary
Nuwellis faces significant financial challenges marked by consistent losses and negative cash flows, despite stable revenue and a strong equity position. The company needs to focus on improving operational efficiency and profitability to ensure long-term sustainability.
Income Statement
45
Neutral
Nuwellis demonstrates modest revenue growth with a 2.8% increase from 2022 to 2023 and a slight decline of 1.4% in 2024. However, the company is grappling with negative profitability as evidenced by significant negative EBIT and net income margins. Despite a decent gross profit margin of approximately 64.9% for 2024, ongoing losses due to high operational costs are concerning.
Balance Sheet
50
Neutral
The company's balance sheet shows a healthy equity position with an equity ratio of 66.2% in 2024, indicating a strong buffer against liabilities. However, the debt-to-equity ratio stands at 0.08, showcasing manageable leverage but returns on equity remain negative due to sustained net losses. The stability is commendable, yet profitability remains a critical issue.
Cash Flow
40
Negative
Cash flow analysis reflects a challenging situation with negative free cash flow, although there is a marked improvement in operating cash flow from 2023 to 2024. The company's reliance on financing activities for liquidity is evident. Free cash flow growth remains negative, indicating ongoing cash burn issues which could impact future operations if not addressed.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue8.32M8.74M8.86M8.54M7.92M7.44M
Gross Profit5.04M5.68M4.98M4.75M4.49M4.06M
EBITDA-3.96M-5.24M-16.36M-4.90M-19.06M-16.65M
Net Income-14.68M-10.62M-20.21M-14.53M-19.58M-15.84M
Balance Sheet
Total Assets9.20M9.86M9.77M24.67M30.42M20.01M
Cash, Cash Equivalents and Short-Term Investments4.45M5.09M3.80M18.31M24.20M14.44M
Total Debt438.00K545.00K760.00K984.00K1.18M339.00K
Total Liabilities18.16M3.33M6.56M12.32M4.47M3.69M
Stockholders Equity-8.96M6.53M3.21M12.36M25.95M16.32M
Cash Flow
Free Cash Flow-8.62M-9.65M-18.18M-15.27M-18.06M-16.87M
Operating Cash Flow-8.61M-9.59M-17.94M-15.15M-17.84M-16.57M
Investing Cash Flow-11.00K-60.00K330.00K14.73M-15.72M-267.00K
Financing Cash Flow12.06M10.96M3.68M9.42M27.87M30.02M

Nuwellis Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.22
Price Trends
50DMA
9.25
Negative
100DMA
22.87
Negative
200DMA
38.11
Negative
Market Momentum
MACD
-1.72
Negative
RSI
33.37
Neutral
STOCH
25.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUWE, the sentiment is Negative. The current price of 5.22 is below the 20-day moving average (MA) of 6.67, below the 50-day MA of 9.25, and below the 200-day MA of 38.11, indicating a bearish trend. The MACD of -1.72 indicates Negative momentum. The RSI at 33.37 is Neutral, neither overbought nor oversold. The STOCH value of 25.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUWE.

Nuwellis Risk Analysis

Nuwellis disclosed 37 risk factors in its most recent earnings report. Nuwellis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Nuwellis Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.82B-0.16-39.78%2.19%21.38%-1.56%
45
Neutral
$4.78M-440.77%-7.72%99.54%
44
Neutral
$3.88M-179.11%37.61%68.37%
43
Neutral
$4.46M-1371.21%-13.90%44.89%
42
Neutral
$8.99M-195.48%-40.47%96.14%
40
Underperform
$5.20M-195.55%65.72%
37
Underperform
$7.38M-101.49%-19.81%93.32%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NUWE
Nuwellis
5.22
-54.84
-91.31%
SINT
Sintx Technologies
3.49
-0.74
-17.49%
HIND
Vyome Holdings
11.51
-1,000.59
-98.86%
VERO
Venus Concept
2.45
-3.62
-59.64%
VTAK
Catheter Precision
3.02
-32.51
-91.50%
AMIX
Autonomix Medical, Inc.
1.01
-10.79
-91.44%

Nuwellis Corporate Events

Product-Related Announcements
Nuwellis Gains FDA Clearance for New Catheter
Positive
Aug 21, 2025

On August 21, 2025, Nuwellis, Inc. announced that it has received FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). This clearance may enhance the company’s product offerings and potentially improve its market position in the medical device industry.

M&A Transactions
Nuwellis Announces Acquisition of Rendiatech, Ltd.
Positive
Aug 19, 2025

On August 19, 2025, Nuwellis, Inc. announced its intention to acquire Rendiatech, Ltd., an Israeli company specializing in urine flow and kidney monitoring technologies. This acquisition aims to enhance Nuwellis’ technology platform by incorporating continuous renal health monitoring, potentially offering clinicians better insights into fluid status and kidney function. The deal is expected to close in the fourth quarter of 2025, subject to due diligence, board approval, and closing conditions.

Delistings and Listing ChangesShareholder MeetingsStock Split
Nuwellis Approves Stock Proposals at Special Meeting
Neutral
Aug 4, 2025

On August 4, 2025, Nuwellis, Inc. held a virtual special meeting of stockholders to discuss several key proposals. The meeting sought approval for the issuance of common stock shares, an increase in authorized shares from 100 million to 200 million, and a reverse stock split to comply with Nasdaq listing requirements. The proposals were approved by a majority vote, with the reverse split aimed at maintaining the company’s Nasdaq listing status.

Delistings and Listing ChangesRegulatory Filings and Compliance
Nuwellis Regains Nasdaq Compliance After Delisting Risk
Positive
Jul 23, 2025

Nuwellis, Inc. received a notice from Nasdaq on June 18, 2025, indicating that its stock price had fallen below $1.00 per share for 30 consecutive trading days, putting it at risk of delisting. However, by July 22, 2025, the company had resolved the issue, and Nasdaq confirmed that Nuwellis was back in compliance with listing standards, allowing its stock to continue trading on the Nasdaq Capital Market.

Executive/Board ChangesStock Split
Nuwellis Appoints John L. Erb as CEO
Neutral
Jul 2, 2025

On June 27, 2025, Nuwellis, Inc. appointed John L. Erb as the Chief Executive Officer and President, solidifying his leadership role after serving as interim CEO since February 2025. Mr. Erb, who has a long history with the company and extensive experience in the medical device sector, will continue to serve as Chairman of the Board. Additionally, the company announced a one-for-forty-two reverse stock split, approved by the board on June 19, 2025, to be effective on July 3, 2025, which aims to consolidate shares and adjust the stock’s market value, impacting shareholders and the company’s trading dynamics.

Delistings and Listing ChangesStock Split
Nuwellis Faces Nasdaq Delisting Due to Stock Price
Negative
Jun 23, 2025

Nuwellis, Inc. has received a deficiency notice from Nasdaq due to its stock price falling below the minimum bid requirement of $1.00 for 30 consecutive trading days. The company, which previously conducted a reverse stock split in June 2024, is not eligible for the compliance period and faces potential delisting unless it requests a hearing. The board plans to implement another reverse stock split to regain compliance, but there is no assurance of success.

Private Placements and FinancingRegulatory Filings and Compliance
Nuwellis Completes Securities Exchange Agreement with CEO
Neutral
Jun 9, 2025

On June 6, 2025, Nuwellis, Inc. filed a Certificate of Designation for Series F-1 Convertible Preferred Stock with the Delaware Secretary of State, authorizing the issuance of 100 shares. This new stock series is similar to the existing Series F Convertible Preferred Stock but includes a conversion limitation to prevent holders from exceeding 19.99% ownership of outstanding common stock. On June 9, 2025, Nuwellis entered into a Securities Exchange Agreement with CEO John L. Erb, exchanging 100 shares of the new Series F-1 Stock for the same number of existing Series F Stock, resulting in Mr. Erb owning 100% of the Series F-1 Stock.

Delistings and Listing ChangesExecutive/Board ChangesShareholder MeetingsStock Split
Nuwellis Approves Reverse Stock Split at Meeting
Neutral
May 22, 2025

On May 20, 2025, Nuwellis held its annual stockholders meeting where key decisions were made. Two Class III directors were elected to the board for three-year terms, and a reverse stock split was approved to help maintain compliance with Nasdaq listing requirements. Additionally, Baker Tilly US, LLP was ratified as the independent public accounting firm for 2025, and provisions were made for potential adjournments to gather more proxy votes if needed.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 21, 2025